Dr Lal PathLabs reported a 15.2% decrease in its net profit for the fourth quarter ending March 31. The company’s net profit stood at Rs 131.3 crore for Q4, down from Rs 154.8 crore in the same period the previous fiscal year, as per its stock exchange filing.
Despite a significant increase in revenue by 16.6% year-on-year to Rs 702.7 crore, compared to Rs 602.6 crore, driven by consistent demand and higher test volumes, the profit decline was notable. The company’s operating performance saw a modest growth, with EBITDA rising by 11% to Rs 186.8 crore from Rs 169 crore a year earlier, as indicated in its regulatory filing.
However, the company faced margin pressure during the quarter, with the EBITDA margin decreasing to 26.6% from 28% in the corresponding period last year. In a move to benefit shareholders, the board has proposed a final dividend of Rs 4 per equity share, representing 40% on a face value of Rs 10 for FY26.
The dividend payout is subject to approval at the upcoming annual general meeting, with the record date set as June 26, 2026, to identify eligible shareholders. Following the financial results announcement, Dr Lal PathLabs’ shares closed 1.7% lower at Rs 1,374 on the NSE on April 30.
Over the past five days, the company’s shares dropped by Rs 41 or 2.90%. However, in the last month, the stock provided a positive return of Rs 50.40 or 3.81%. In the last six months, the shares declined by nearly Rs 194 or 12.36%. Year-to-date, investors experienced a negative return of Rs 135.80 or 8.99%.
